Highlights Daré Bioscience, Inc.

Equities

DARE

US23666P2002

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
3.32 ^USD	+6.07%		+7.44%	-10.46%

Jun. 27	Dare Bioscience to Implement 1-for-12 Reverse Stock Split	MT
Jun. 24	Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Dare Bioscience to Implement 1-for-12 Reverse Stock Split	Jun. 27	MT
Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder	Jun. 24	CI
Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3	May. 15	MT
Earnings Flash (DARE) DARE BIOSCIENCE Posts Q1 Revenue $9,302	May. 14	MT
Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC	Apr. 30	CI
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	Apr. 29	CI
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	Apr. 23	CI
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	Jan. 31	CI
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	Dec. 20	CI
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	Dec. 07	MT
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug Application for DARE-VVA1	Dec. 07	CI
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	Dec. 04	CI
Dar Bioscience, Inc. and Premier Research International LLC Extend Strategic Partnership to Accelerate the Clinical Development of Dar's Novel Women's Health Programs	Nov. 20	CI
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 09	CI
Daré Bioscience, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-10	CI
Dare Bioscience Awarded $385,000 Grant to Develop Therapy for Idiopathic Preterm Birth	23-07-31	MT
Daré Bioscience, Inc. Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth	23-07-31	CI
Dare Bioscience, Inc. Announces Additional Positive Data from Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women	23-07-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Daré Bioscience, Inc.

Equities

DARE

US23666P2002

Highlights

Filters